Autologous peripheral blood stem cell transplantation: Predictors for haematopoietic reconstitution

National Medical Journal of India

Volumn 16, Issue 5, 2003, Pages 255-259

  Bedi, Rajeev ^a   Kumar, Lalit ^a   Kochupillai, V ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; STEM CELL FACTOR; THROMBOPOIETIN;

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER; CELL ASSAY; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMING UNIT GM; CORRELATION ANALYSIS; DOSE RESPONSE; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE COUNT; MONONUCLEAR CELL; NONHUMAN; PREDICTION; REVIEW; STEM CELL MOBILIZATION;

ANTIGENS, CD34; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RESEARCH; TRANSPLANTATION, AUTOLOGOUS;

EID: 0344307640     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-13.
2. Philip T, Guglielmi C, Hagenbeck A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
3. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-7.
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
5. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
6. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:1905-14.
7. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997;89:2233-58.
8. International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry (IBMTR/ABMTR). Newsletter 2000;7:3-10.
9. Gratwohl A, Passweg J, Baldomero H, Hermans J. Blood and Marrow transplantation activity in Europe in 1997. European Group for Blood and Marrow Transfusion (EBMT). Bone Marrow Transplant 1999;24:231-45.
10. Rowley SD, Zuehlsdorf M, Braine HG, Colvin OM, Davis J, Joenes RJ, et al. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroxyperoxy-cyclophosphamide-purged bone marrow. Blood 1987;70:271-5.
11. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360-77.
12. Passweg JR, Meyer-Monard S, Gregor M, Favre G, Heim D, Ebnoether M, et al. High stem cell dose will not compensate for T cell depletion in allogeneic, non-myeloablative stem cell transplantation. Bone Marrow Transplant 2002;30:267-71.
13. 6CD34(+)/kg: An analysis of variables concerning mobilisation and engraftment. Hematol J 2000;1: 374-81.
14. Imbert-Marcille BM, Tang XW, Lepelletier D, Besse B, Moreau P, Billaudel S, et al. Human herpesvirus 6 infection after autologous or allogeneic stem cell transplantation: A single-center prospective longitudinal study of 92 patients. Clin Infect Dis 2000;31:881-6.
15. Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control 2003;10: 9-16.
16. Nakahata T, Ogawa M. Identification in culture of a class of hematopoietic colony-forming units with extensive capability to self-renew and generate multipotential hematopoietic colonies. Proc Natl Acad Sci USA 1982;79:3843-7.
17. McNiece I. The CD34+ve Thy1+ cell population: Are they all stem cells? Exp Hematol 2000;28:1312-14.
18. Goodell MA, Rosenzweig M, Kim H, Marks DF, De Maria M, Paradis G, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997;3:1337-45.
19. Morrison SJ, Shah NM, Anderson DJ. Regulatory mechanisms in stem cell biology. Cell 1997;88:287-98.
20. Quesenbuerry PJ, Colvin GA. Hematopoietic stem cells, progenitor cells and cytokines. In: Williams WJ, Beutler E, Lichtman M, Coller B, Kipps JJ, Seligsohn U, et al. (eds). William's hematology. 6th ed. New York:McGraw-Hill, 1999:155-6.
21. Hartmann O, Le Cooller AG, Blaise D, Michon J, Philip I, Norol F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumours and lymphomas:, Hematologic recovery and costs, Arandomized controlled trial. Ann Intern Med 1997;126.600-7.
22. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, et al, Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgastrim in breast cancer patients. Blood 1997;90:2939-51.
23. Lyman SD. Biologic effects and potential clinical applications of Flt-3 ligand. Curr Opin Hematol 1998;5:192-6.
24. Kumar L, Gulati SC. Peripheral stem-cell transplantation. Lancet 1995;346(suppl):S9.
25. Hassan HT, Stockchlader M, Schleimer B, Kruger W, Zander AR. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transplant Immunol 1996;4:319-23.
26. Talmadge JE, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D, et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997; 19:161-72.
27. Gordon MY. Physiological mechanisms in BMT and haemopoiesis: Revisited. Bone Marrow Transplant 1993;11: 193-7.
28. Andrews SRG, Singer JW, Bernstein ID. Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986;67:842-7.
29. Johnsen HE, Baech J, Nikolajsen K. Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: Report from the third workshop. J Hematother 1999;8:15-28.
30. Demirer T, Gooley T, Buckner CD, Patersen FB, Lilleby K, Rowley S, et al. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation Bone Marrow Transplant 1995;15:907-13.
31. Mehta J, Powles R, Horton C, Treleaven J, Singhal S. Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia. Bone Marrow Transplant 1996;18:319-24.
32. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-cs)f: An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-31.
33. Weaver CH, Hazelton B, Birch R , Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9.
34. To LB, Roberts MM, Rawling CM, et al. Establishment of a clinical threshold cell dose: Correlation between CFU-GM and duration of aplasia. In: Wunder E, Sovalat H, Henon PR, Serike S (eds). Hematopoietic stem cells: The Mulhouse Manual. Dayton, DH: Alpha Med, 1994:15.
35. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998;91:3148-55.
36. Weaver CH, Potz J, Redmond J; Tauer K, Schwartzberg LS, Kaywin P, et al. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone Marrow Transplant 1997;19,1103-10.
37. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995;13:2547-55.
38. Figuerres E, Haut PR, Olzewski M, Kletzel M. Analysis of parameters affecting engraftment in children undergoing autologous peripheral blood stem cell transplants, Bone Marrow Transplant 2000;25:583-8.
39. Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L, Sanchez-Cortes E, Ayala-Sanchez M, Guevara-Moreno ME, et al. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant 2000;25: 1141-6.
40. Andre M, Baudoux E, Bron D, Canon JL, D'Hondt V, Fassotte MF, et al. Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003;43:50-7.
41. Bedi R, Kumar L, Bhutani M, Sharma A, Kochupillai V. Autologous peripheral blood stem cell transplantation: A study of engraftment kinetics. Indian J Med Paediatr Oncol 2003 (in press).
42. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;17:1031-9.
43. Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): A randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002;116:468-74.
44. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059-64.